Skip to main content

Table 3 Association between methylation patterns of MLH1 and MGMT and mutational status

From: Correlation of MLH1 and MGMTexpression and promoter methylation with genomic instability in patients with thyroid carcinoma

Methylation status

Mutational status

N (%)

p

BRAF V600E*

MLH1

Methylated

Positive

4/20 (20%)

0.048

  

Negative

10/19 (53%)

 
 

Unmethylated

Positive

16/20 (80%)

 
  

Negative

9/19 (47%)

 

MGMT

Methylated

Positive

14/20 (70%)

0.333

  

Negative

10/19 (53%)

 
 

Unmethylated

Positive

6/20 (30%)

 
  

Negative

9/19 (47%)

 

RET/PTC*

MLH1

Methylated

Positive

8/16 (50%)

1.000

  

Negative

10/19 (53%)

 
 

Unmethylated

Positive

8/16 (50%)

 
  

Negative

9/19 (47%)

 

MGMT

Methylated

Positive

9/16 (56%)

1.000

  

Negative

10/19 (53%)

 
 

Unmethylated

Positive

7/16 (44%)

 
  

Negative

9/19 (47%)

 

Transitions (IDH1 + NRAS)

MLH1

Methylated

Positive

5/11 (45%)

1.000

  

Negative

13/25 (52%)

 
 

Unmethylated

Positive

6/11 (55%)

 
  

Negative

12/25 (48%)

 

MGMT

Methylated

Positive

9/11 (82%)

0.268

  

Negative

15/25 (60%)

 
 

Unmethylated

Positive

2/11 (18%)

 
  

Negative

10/25 (40%)

 

Point mutations (BRAF + IDH1 + NRAS)

MLH1

Methylated

Positive

14/41 (34%)

0.199

  

Negative

13/25 (52%)

 
 

Unmethylated

Positive

27/41 (66%)

 
  

Negative

12/25 (48%)

 

MGMT

Methylated

Positive

29/41 (71%)

0.426

  

Negative

15/25 (60%)

 
 

Unmethylated

Positive

12/41 (29%)

 
  

Negative

10/25 (40%)

 
  1. * Analysis performed only in the PTC group.
  2. Negative group comprises only samples without any of the alterations investigated.